Who is sponsoring NCT02354768?

NCT02354768 is sponsored by University Hospital, Strasbourg, France.

What drugs are being tested in NCT02354768?

Interventions in NCT02354768: Effects of lanreotide with current anti-diarrheal treatments (diosmectite and loperamide), Effects of current anti-diarrheal treatments (diosmectite and loperamide) alone.

What condition does NCT02354768 study?

NCT02354768 studies High Output Stoma.

Is NCT02354768 still recruiting?

NCT02354768 is currently terminated. Last updated 7 March 2018.

Last reviewed 2018-03-07 · How we verify

NCT02354768: ILEHOS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of Lanreotide Efficacity in High Output Stoma: a Multicentric Randomized Study

Terminated Phase 3 Last updated 7 March 2018

What this trial tests

Phase 3 trial testing Effects of lanreotide with current anti-diarrheal treatments (diosmectite and loperamide) in High Output Stoma in 19 participants. Terminated before completion.

Timeline

22 October 2015

Primary endpoint
31 December 2017

26 January 2018

Quick facts

Lead sponsor	University Hospital, Strasbourg, France
Phase	Phase 3
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	19
Start date	22 October 2015
Primary completion	31 December 2017
Estimated completion	26 January 2018
Sites	6 locations across France

Drugs / interventions tested

Effects of lanreotide with current anti-diarrheal treatments (diosmectite and loperamide) — full drug profile →
Effects of current anti-diarrheal treatments (diosmectite and loperamide) alone — full drug profile →

Conditions studied

High Output Stoma — all drugs for High Output Stoma →

Sponsor

University Hospital, Strasbourg, France

Who can join

18 and older, any sex, with High Output Stoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Dehydration is a major problem of high output stoma with a 17% rate of readmission at 30 days. Dehydratations are resulting of significant electrolyte loss: sodium, potassium and renal failure. Nowadays, there are no recommendations nor national nor international for high output ileostomy treatment. Apart from the anti-diarrhea treatments used in current practice, somatostatin analogs have proven efficacy in the literature. Theses analogs permit to decrease significantly gastrointestinal secretions. Several teams use these analogs in order to decrease the flow of highly productive ileostomy. The aim of the study is to evaluate the efficacy first line treatment with lanreotide associated with current anti-diarrheal treatment for patients with high output ileostomy (or greater throughput 1.5l / 24h) with or without associated dehydration

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Lanreotide in the prevention and management of high-output ileostomy after colorectal cancer surgery.
Cuyle PJ, Engelen A, Moons V, Tollens T, et al · · 2018 · cited 3× · PMID 29888099 · DOI 10.1080/21556660.2018.1467916

Verify or expand the search:

Other University Hospital, Strasbourg, France trials

Trials by the same sponsor.

NCT07418554 — Sleep Disturbances in Children and Adolescents With Post-traumatic Stress Disorder (PTSD): a Randomized Double-blind Pla · Phase 3 · not yet recruiting
NCT07108582 — Reducing Chronic Pain After Lung Surgery: A Trial of Limiting NSAIDs During Recovery · Phase 3 · not yet recruiting
NCT07302646 — Optimizing Reduced-Flow, Low-Volume Contrast Protocols for Cerebral Angiography in Unruptured Aneurysms · NA · not yet recruiting
NCT07273968 — Clinical Study Evaluating the Effect of Virtual Reality on Reducing Patients' Anxiety During Wisdom Teeth Extraction · NA · not yet recruiting
NCT07214103 — Phase IIb Multicenter Randomized Controlled Trial Evaluating the Efficacy of Sivelestat in Patients With Septic Coagulop · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02354768 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Strasbourg, France
Last refreshed: 7 March 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02354768.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing